John Friend

1.9k total citations · 1 hit paper
38 papers, 1.4k citations indexed

About

John Friend is a scholar working on Physiology, Molecular Biology and Cancer Research. According to data from OpenAlex, John Friend has authored 38 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Physiology, 10 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in John Friend's work include Nutrition and Health in Aging (15 papers), Adipose Tissue and Metabolism (11 papers) and Cancer, Hypoxia, and Metabolism (4 papers). John Friend is often cited by papers focused on Nutrition and Health in Aging (15 papers), Adipose Tissue and Metabolism (11 papers) and Cancer, Hypoxia, and Metabolism (4 papers). John Friend collaborates with scholars based in United States, United Kingdom and Australia. John Friend's co-authors include Jennifer S. Temel, David C. Currow, Elizabeth Manning Duus, Kenneth C.H. Fearon, Amy P. Abernethy, José M. Garcia, Ying Yan, B. Rajagopalan, T. J. Stallard and Ying Yan and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

John Friend

38 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials

2016 439 citations Jennifer S. Temel, Amy P. Abernethy et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Friend United States	13	768	266	216	215	195	38	1.4k
Noriaki Takabatake Japan	20	383 0.5×	207 0.8×	673 3.1×	181 0.8×	80 0.4×	39	1.4k
Ammon Handisurya Austria	21	280 0.4×	156 0.6×	83 0.4×	244 1.1×	267 1.4×	33	1.3k
Ryo Tachikawa Japan	19	312 0.4×	101 0.4×	791 3.7×	209 1.0×	62 0.3×	80	1.2k
Motonari Fukui Japan	15	286 0.4×	92 0.3×	562 2.6×	120 0.6×	78 0.4×	71	1.1k
Markus von Flüe Switzerland	21	419 0.5×	127 0.5×	327 1.5×	94 0.4×	1.3k 6.6×	91	1.7k
Antonio Pio Tortorelli Italy	16	239 0.3×	74 0.3×	248 1.1×	45 0.2×	379 1.9×	50	869
Haluk Şavlı Türkiye	19	154 0.2×	138 0.5×	86 0.4×	372 1.7×	139 0.7×	38	1.2k
Jens Hillingsø Denmark	19	138 0.2×	124 0.5×	178 0.8×	229 1.1×	725 3.7×	90	1.3k
Serge Motte Belgium	18	127 0.2×	158 0.6×	344 1.6×	150 0.7×	354 1.8×	58	1.1k
Shekhar Ghamande United States	18	238 0.3×	78 0.3×	388 1.8×	127 0.6×	184 0.9×	70	952

Countries citing papers authored by John Friend

Since Specialization

Citations

This map shows the geographic impact of John Friend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Friend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Friend more than expected).

Fields of papers citing papers by John Friend

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Friend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Friend. The network helps show where John Friend may publish in the future.

Co-authorship network of co-authors of John Friend

This figure shows the co-authorship network connecting the top 25 collaborators of John Friend. A scholar is included among the top collaborators of John Friend based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Friend. John Friend is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hickey, Matthew D., Elizabeth Imbert, Ayesha Appa, et al.. (2022). HIV Treatment Outcomes in POP-UP: Drop-in HIV Primary Care Model for People Experiencing Homelessness. The Journal of Infectious Diseases. 226(Supplement_3). S353–S362. 23 indexed citations

Currow, David C., Jennifer S. Temel, Amy P. Abernethy, et al.. (2017). ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Annals of Oncology. 28(8). 1949–1956. 118 indexed citations

Currow, David C., Jennifer S. Temel, Amy Pickar Abernethy, John Friend, & R. Giorgino. (2017). Body weight response with anamorelin in advanced non-small cell lung cancer (NSCLC) patients with anorexia/cachexia: Pooled analysis of two phase III trials.. Journal of Clinical Oncology. 35(15_suppl). 10097–10097. 3 indexed citations

Temel, Jennifer S., Amy P. Abernethy, David C. Currow, et al.. (2016). Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet Oncology. 17(4). 519–531. 439 indexed citations breakdown →

Currow, David C., Jennifer S. Temel, Amy Pickar Abernethy, et al.. (2016). Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m²): Post-hoc analysis of two phase III studies.. Journal of Clinical Oncology. 34(26_suppl). 203–203. 1 indexed citations

Temel, Jennifer S., David C. Currow, Kenneth C. H. Fearon, et al.. (2015). Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2).. Journal of Clinical Oncology. 33(15_suppl). 9500–9500. 6 indexed citations

Currow, David C., Jennifer S. Temel, Kenneth C. H. Fearon, et al.. (2015). A safety extension study of anamorelin in advanced non-small cell lung cancer patients with cachexia: ROMANA 3.. Journal of Clinical Oncology. 33(15_suppl). e20715–e20715. 5 indexed citations

Currow, David C., Jennifer S. Temel, Kenneth C.H. Fearon, et al.. (2015). 1603 ROMANA 3: A safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. European Journal of Cancer. 51. S239–S239. 2 indexed citations

Salsman, John M., Jennifer L. Beaumont, Katy Wortman, et al.. (2014). Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Supportive Care in Cancer. 23(5). 1355–1364. 18 indexed citations

10.

Garcia, José M., et al.. (2014). Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. The Lancet Oncology. 16(1). 108–116. 163 indexed citations

11.

Abernethy, Amy Pickar, David C. Currow, Kenneth Fearon, et al.. (2014). Anamorelin for the treatment of cancer anorexia-cachexia: Baseline characteristics from three phase III clinical trials (the ROMANA program).. Journal of Clinical Oncology. 32(15_suppl). e20694–e20694. 1 indexed citations

12.

Temel, Jennifer S., David C. Currow, Kenneth C.H. Fearon, et al.. (2014). Anamorelin for the Treatment of Cancer Anorexia-Cachexia in Nsclc: Results from the Phase 3 Studies Romana 1 and 2. Annals of Oncology. 25. v1–v1. 11 indexed citations

13.

Garcia, José M., et al.. (2012). Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Supportive Care in Cancer. 21(1). 129–137. 131 indexed citations

14.

Garcia, José M., Ying Yan, Elizabeth Manning Duus, & John Friend. (2012). Anamorelin's Effects on Appendicular Lean Body Mass in Cancer Patients with Cachexia; Results from A Phase II Randomized, Double Blind, Multicenter Study. Annals of Oncology. 23. ix512–ix512. 3 indexed citations

15.

Pietra, Claudio, John Friend, & Beverley Greenwood–Van Meerveld. (2011). Preclinical Pharmacological Profile of Ipamorelin a Novel Gastroprokinetic for Intestinal Dysmotility. Gastroenterology. 140(5). S–285. 1 indexed citations

16.

Campbell, I. A., L P Ormerod, John Friend, Peter Jenkins, & R. J. Prescott. (1993). Six months versus nine months chemotherapy for tuberculosis of lymph nodes: Final results. Respiratory Medicine. 87(8). 621–623. 63 indexed citations

17.

McGavin, C R, et al.. (1985). Short course chemotherapy for tuberculosis of lymph nodes: a controlled trial. British Thoracic Society Research Committee.. BMJ. 290(6475). 1106–1108. 42 indexed citations

18.

Friend, John, et al.. (1980). β‐Adrenoceptor antagonists in l‐tryptophan and l‐DOPA induced behavioural syndromes. British Journal of Pharmacology. 68(3). 176–176. 5 indexed citations

19.

Rajagopalan, B., et al.. (1979). Blood flow in pulmonary veins: II The influence of events transmitted from the right and left sides of the heart. Cardiovascular Research. 13(12). 677–683. 73 indexed citations

20.

Scher, Jonathan, et al.. (1972). A comparison of prostaglandin F2 alpha and oxytocin in the induction of labour.. PubMed. 46(51). 2009–12. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact